Lithium Carbonate: A Clinical Study
Abstract
Lithium carbonate has been widely acclaimed as a useful drug in the treatment of manic-depressive psychoses. The results of this clinical study emphasize that lithium is highly beneficial in preventing and alleviating acute mania and the hypomanic aspects of schizo-affective psychoses. When used alone, lithium was found to be relatively ineffective as an antidepressant. However, in combination with a tricyclic or MAO-inhibiting antidepressant, it was often effective in alleviating depressions, including those refractory to single psychopharmacological agents.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
